

## Enanta Pharmaceuticals Inc

### CORTELLIS COMPANY DETAILED PIPELINE REPORT

A comprehensive coverage of the the company's drug pipeline portfolio including detailed product records.

Publication Date: 20-Jun-2013

#### THOMSON REUTERS

3 Times Square  
New York, New York 10036  
United States

Tel: +1 646 223 4000

[thomsonreuters.com](http://thomsonreuters.com)

[Return to Table of Contents](#)



## ABOUT CORTELLIS COMPANY DETAILED PIPELINE REPORT

Thomson Reuters provides the knowledge, tools, and expertise to help support drug discovery and development activities, IP portfolio optimization, identification of licensing and partnering opportunities, delivery of successful regulatory submissions, and the ability to keep current with the rapidly-changing pharmaceutical and chemical markets, supporting informed, early decisions.

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information. From drug discovery and development activities to patent reports, the latest deals, and partnering opportunities, *Cortellis* can provide the confidence to make the most informed business decisions, faster. *Cortellis for Competitive Intelligence* provides accurate and validated information on pharmaceutical and biotechnology companies globally, their drug pipelines, deals, patents, and clinical trials, plus breaking industry news and conference coverage. All contained in one simple, highly intuitive research platform.

*Cortellis* Company Detailed Pipeline reports are the second in a series of that track pharmaceutical and biotechnology companies worldwide. All *Cortellis for Competitive Intelligence* content is subject to the most comprehensive editorial review process available, conducted by scientists, pharma professionals, regulatory experts, and generics specialists. Featuring timely drug pipeline information expertly uncovered and integrated from over 400 global meetings each year, you'll always be on top of the latest developments.

Chosen by leading life sciences companies, their executives and investors, *Cortellis for Competitive Intelligence* accelerates your deal-making and gives you timely insights on the development landscape.

**Discover undiscovered opportunities in drug development and licensing faster with *Thomson Reuters Cortellis™ for Competitive Intelligence***

### DISCLAIMER

The information contained in this report is based on sources believed to be correct but Thomson Reuters does not guarantee the accuracy, timeliness, or completeness of this information. Opinions, if any, are those held by the author of any individual report or article at the time of initial publication and do not necessarily reflect the views of Thomson Reuters.

Information in this report on companies is intended for reference use only, and does not constitute a recommendation to buy or sell any particular security or other investment and does not constitute an offer to buy from or sell to any particular investor. Any company or securities mentioned in this report may not be suitable for any particular investor, depending on that investor's financial position and needs.

[Return to Table of Contents](#)



## GLOSSARY

### Number of Drugs in Active Development

Number of drugs associated with the company or subsidiary that are currently in active development, i.e. the development status for the drug(s) is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Number of Inactive Drugs

Number of drugs associated with the company or subsidiary that are currently classified as inactive, i.e. where the development status for the drug(s) is one of the following: No Development Reported, Discontinued, or Withdrawn.

### Number of Patents as Owner

Number of patents associated with the company where the company is listed as owner; i.e. the relationship type (or way the patent refers to the company) is: Patent Assignee/Owner, Patent owner (not assignee), Licensee for development and marketing, Licensee – marketing only (Distributor), Patent assignee of family member, Inferred assignee.

### Number of Patents as Third Party

Number of patents associated with the company where the company is listed as third party; i.e. the relationship type (or way the patent refers to the company) is: Patent assignee (not owner), Ex-Licensee for development and marketing, Ex-Licensee marketing only (Distributor), Customer of technology, Ex-Customer of technology, Patent opponent or infringer, Affiliate organization of inventor, Owner of underlying technology.

### Patents summary table

This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

### Number of Deals

A count of deals where the company or one of its subsidiaries is the primary company.

### Key Indications

Displays top ten key indications for the company and its subsidiaries based on frequency (indications occurring with high and identical frequency are always included, and this may result in more than ten Key Indications being listed). Includes both indications associated with patents where the company is patent owner and indications associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

### Key Target-based Actions

Displays top ten key target-based actions for the company and its subsidiaries based on frequency (actions occurring with high and identical frequency are always included, and this may result in more than ten Key Target-based Actions being listed). Includes both target-based actions associated with patents where the company patent owner and target-based actions associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended. A target-based action is one that is associated with a target.

### Key Technologies

Displays top ten key technologies for the company and its subsidiaries based on frequency (technologies occurring with high and identical frequency are always included, and this may result in more than ten Key Technologies being listed). Includes both key technologies associated with patents where the company relationship is patent owner and key technologies associated with drugs in active development. A drug is classified as 'active' if it features on a row (or rows) in the current development status table where the status is one of the following: Discovery, Clinical, Phase I, Phase II, Phase III, Pre-registration, Registered, Launched, or Suspended.

[Return to Table of Contents](#)



TABLE OF CONTENTS

Company Overview..... 5

Company Profile..... 6

Product Portfolio Summary..... 7

Product Portfolio Drug Pipeline Detail..... 10

    Phase 3 Clinical..... 11

    Phase 2 Clinical..... 16

    Phase 1 Clinical..... 24

    Discovery..... 25

    Suspended..... 50

[Return to Table of Contents](#)

# Enanta Pharmaceuticals Inc

## COMPANY OVERVIEW

<b>Company Name</b>	Enanta Pharmaceuticals Inc
<b>Parent Company Name</b>	Enanta Pharmaceuticals Inc
<b>Website</b>	http://www.enanta.com/
<b>Country</b>	US
<b>Number of Drugs in Active Development</b>	11
<b>Number of Inactive Drugs</b>	4
<b>Number of Patents as Owner</b>	158
<b>Number of Patents as Third Party</b>	0
<b>Number of Deals</b>	5
<b>Key Indications</b>	Hepatitis C virus infection,Bacterial infection,Gram positive bacterium infection,Bacterial respiratory tract infection,Hepatitis B virus infection,Neisseria gonorrhoeae infection,HIV infection,Inflammatory disease,Cystic fibrosis,Viral infection
<b>Key Target-based Actions</b>	Hepatitis C virus NS3 protease inhibitor,Hepatitis C virus protein NS5A inhibitor,Hepatitis C virus NS5B polymerase inhibitor,Peptidylprolyl isomerase inhibitor,Flavivirus NS3 protease inhibitor,Hepatitis C virus NS2-NS3 protease inhibitor,Hepatitis C virus protease inhibitor
<b>Key Technologies</b>	Small molecule therapeutic,Antibiotic,Oral formulation,Prodrug,Intravenous formulation,Dermatological formulation,Inhalant formulation,Drug combination,Antibiotic resistance,Local formulation unspecified,Systemic formulation unspecified,Tablet formulation

## COMPANY PROFILE

### SUMMARY

Enanta Pharmaceuticals is a drug discovery company specializing in the development of small molecule anti-infective agents, especially macrolide and ketolide antibiotics.

### LICENSING AGREEMENTS

In March 2003, Enanta received a milestone payment from Chiron for the completion of the first phase of Enanta's research for the discovery and development of small molecule HCV therapeutics. In September 2002, Enanta signed an exclusive, joint collaboration with Chiron for the discovery and development of small molecule HCV therapeutics. Enanta was to apply its macrocyclic chemistry and medicinal chemistry expertise to design and synthesize of compounds targeting enzymes involved in the replication of the virus. Chiron gave Enanta a non-exclusive license to its HCV patents and Enanta gave Chiron an exclusive worldwide license to compounds that were developed. Enanta was also to receive research funding, milestone payments and royalties, while Chiron was to be responsible for preclinical and clinical development, manufacturing and sales and marketing.

### FINANCIAL

In March 2013, Enanta announced the pricing of its initial public offering of 4 million common stock shares at a price of US \$14 each. The shares traded on the NASDAQ Global Select Market under the symbol 'ENTA'. The underwriters were granted a 30-day option to buy up to an additional 0.6 million common stock shares to cover over-allotments. The offering was expected to close on March 26, 2013; later that month, the offering was closed.

In November 2012, Enanta filed a registration statement with the U.S. Securities and Exchange Commission for proposed initial public offering of its common stock.

In August 2004, Enanta raised \$20 million in new financing, including contributions from Shionogi & Co Ltd, in order to advance its bridged bicyclic ketolide, EP-013420, into phase I trials, and to progress the company's discovery-stage anti-infective programs.

[Return to Table of Contents](#)



In January 2004, Enanta raised \$12 million in financing to advance its lead macrolide antibiotic program into clinical trials.

In June 2002, raised \$18 million in a private financing.


In 1999, Enanta raised \$5.1 million of equity financing and in July 2000, received \$20 million in a second round of private financing.

PRODUCT PORTFOLIO SUMMARY

DRUGS

Drugs by Indication

Active Drugs by Indication Chart




Drugs by Indication Table

Indication	Active	Inactive	Total
Infectious disease	11	3	14
Gastrointestinal disease	6	2	8
Inflammatory disease	6	2	8
Respiratory disease	1	2	3
Immune disorder	0	1	1
Dermatological disease	0	1	1

[Return to Table of Contents](#)

## Drugs by Highest Status

Active Drugs by Highest Status Chart



Drugs by Highest Status Table

Development Status	Number of Drugs
Phase 3 Clinical	1
Phase 2 Clinical	1
Phase 1 Clinical	1
Discovery	7
Suspended	1
Discontinued	2
No Development Reported	2

## DEALS

Deal Type	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Drug - Funding	1	0	0	0	1
Drug - Development/Commercialization License	3	0	1	0	4

[Return to Table of Contents](#)



## CLINICAL TRIALS

### Trials by Condition Studied

Condition Studied	Ongoing	All
Infectious disease	0	9
Respiratory disease	0	4
Gastrointestinal disease	0	2
Inflammatory disease	0	2
Dermatological disease	0	1

### Trials by Phase

Phase	Ongoing	All
Phase 2	0	3
Phase 1	0	6

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## PATENTS \*

Indication	As Owner	As Third Party	Total
Cardiovascular disease	3	0	3
Endocrine disease	2	0	2
Gastrointestinal disease	118	0	118
Genitourinary disease	1	0	1
Growth disorder	2	0	2
Degeneration	2	0	2
Immune disorder	14	0	14
Musculoskeletal disease	9	0	9
Neoplasm	4	0	4
Ocular disease	3	0	3

[Return to Table of Contents](#)





Metabolic disorder	3	0	3
Mouth disease	2	0	2
Neurological disease	2	0	2
Respiratory disease	38	0	38
Infectious disease	149	0	149
Inflammatory disease	121	0	121
Otorhinolaryngological disease	8	0	8
Gynecology and obstetrics	2	0	2
Temperature disorder	1	0	1
Dermatological disease	11	0	11
Ulcer	2	0	2
Surgical procedure	3	0	3

\* This table represents a summary of the core patent coverage for this company covering Therapeutic EP, US and WO patents since 1990 only.

[Return to Table of Contents](#)

## PRODUCT PORTFOLIO DRUG PIPELINE DETAIL

**PLEASE NOTE:** Highest status refers to highest development of that drug for one of the active companies

### ABT-450 + ritonavir + ABT-267 (oral, HCV infection), AbbVie/Enanta

#### ABT-450 + ritonavir + ABT-267 (oral, HCV infection), AbbVie/Enanta SNAPSHOT

<b>Drug Name</b>	ABT-450 + ritonavir + ABT-267 (oral, HCV infection), AbbVie/Enanta
<b>Key Synonyms</b>	
<b>Originator Company</b>	Enanta Pharmaceuticals Inc
<b>Active Companies</b>	AbbVie Inc;Enanta Pharmaceuticals Inc
<b>Inactive Companies</b>	Abbott Laboratories
<b>Highest Status</b>	Phase 3 Clinical
<b>Active Indications</b>	Hepatitis C virus infection
<b>Target-based Actions</b>	Hepatitis C virus NS3 protease inhibitor;Hepatitis C virus protein NS5A inhibitor
<b>Other Actions</b>	Hepatitis C virus replication inhibitor
<b>Technologies</b>	Drug combination;Oral formulation;Tablet formulation;Small molecule therapeutic
<b>Last Change Date</b>	18-Jun-2013

#### ABT-450 + ritonavir + ABT-267 (oral, HCV infection), AbbVie/Enanta DEVELOPMENT PROFILE

##### SUMMARY

Enanta and AbbVie, following its spin-out from Abbott in January 2013, are developing a fixed-dose tablet formulation containing the hepatitis C virus (HCV) NS3/4A protease inhibitor ABT-450 boosted with ritonavir (ABT-450/r) and the NS5A inhibitor ABT-267 for the potential oral treatment of HCV infection. In October 2012, a phase III trial was initiated to study interferon-free treatment with the co-formulated product (ABT-450/r/ABT-267) plus the NS5B polymerase inhibitor ABT-333 and ribavirin in HCV genotype 1 patients. In December 2012, a phase III trial began to assess ABT-450/r/ABT-267, administered once daily, plus ABT-333, with and without ribavirin. In January 2012, a phase II trial was initiated in Japan.

#### ABT-450 + ritonavir + ABT-267 (oral, HCV infection), AbbVie/Enanta DEVELOPMENT STATUS

##### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
AbbVie Inc	Hepatitis C virus infection	US	Phase 3 Clinical	02-Jan-2013
Enanta Pharmaceuticals Inc	Hepatitis C virus infection	US	Phase 3 Clinical	02-Jan-2013
AbbVie Inc	Hepatitis C virus infection	Japan	Phase 2 Clinical	31-Jan-2012
Enanta Pharmaceuticals Inc	Hepatitis C virus infection	Japan	Phase 2 Clinical	31-Jan-2012

[Return to Table of Contents](#)



Company	Indication	Country	Development Status	Date
Abbott Laboratories	Hepatitis C virus infection	US	Discontinued	02-Jan-2013

### ABT-450 + ritonavir + ABT-267 (oral, HCV infection), AbbVie/Enanta CHEMICAL STRUCTURES

CAS Registry Number:	Confidence Level:
155213-67-5	1
Name	Type
ritonavir	BANN; INN; USAN
Norvir	Trade Name
ABT-538	Research Code
A-84538	Research Code
Abbott-84538	Research Code

### ABT-450 + ritonavir + ABT-267 (oral, HCV infection), AbbVie/Enanta DRUG NAMES

Names	Type
ABT-450/r/ABT-267	
ABT-450 + ritonavir + ABT-267 (oral, HCV infection), Abbott	
ABT-450 + ritonavir + ABT-267 (oral, HCV infection), AbbVie/Enanta	
ABT-450/r + ABT-267 (oral, HCV infection), Abbott	

### ABT-450 + ritonavir + ABT-267 (oral, HCV infection), AbbVie/Enanta CLINICAL TRIALS

#### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All

[Return to Table of Contents](#)

Hepatitis C virus infection											
0	0	7	7	3	3	0	0	0	0	10	10

Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	7	7	3	3	0	0	0	0	10	10


Phase Definitions

- Phase 3 Clinical**  
 Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)
- Phase 2 Clinical**  
 Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)
- Phase 1 Clinical**  
 Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

ABT-450 + ritonavir + ABT-267 (oral, HCV infection), AbbVie/Enanta DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




[Return to Table of Contents](#)

Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Enanta Pharmaceuticals Inc	1	0	0	0	1
Abbott Laboratories	0	0	1	0	1

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

PATENTS


Patents by Parent Company Chart



Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
AbbVie Inc	2	0	2

Patents by Drug Relationship Type Chart



[Return to Table of Contents](#)

Patents by Drug Relationship Type Table

Drug Relationship	Total
Component of Combination	2

## ABT-450

### ABT-450 SNAPSHOT

Drug Name	ABT-450
Key Synonyms	
Originator Company	Chiron Corp
Active Companies	AbbVie Inc;Enanta Pharmaceuticals Inc
Inactive Companies	Abbott Laboratories;Chiron Corp
Highest Status	Phase 2 Clinical
Active Indications	Hepatitis C virus infection
Target-based Actions	Hepatitis C virus NS3 protease inhibitor
Other Actions	Hepatitis C virus replication inhibitor
Technologies	Oral formulation;Capsule formulation;Tablet formulation;Small molecule therapeutic
Last Change Date	10-May-2013

### ABT-450 DEVELOPMENT PROFILE

#### SUMMARY

Enanta, under license from Chiron (now Novartis) and in collaboration with AbbVie (following its spin-out from Abbott in January 2013), is developing ABT-450, a hepatitis C virus (HCV) NS3/4A protease inhibitor, for the potential oral treatment of HCV infection,. In March 2010, a phase II trial began. In October 2011, a phase II study of a combination of ABT-450 boosted with ritonavir (ABT-450/r) with the NS5A inhibitor ABT-267 and/or the NS5B polymerase inhibitor ABT-333, with or without ribavirin, began ; in October 2012, initial data were reported.

Abbott is also developing a combination of ABT-450/r and ABT-267 in a fixed-dose tablet formulation (ABT-450/r/ABT-267). In October 2012, a phase III trial of ABT-450/r/ABT-267 with ABT-333 and ribavirin began.

### ABT-450 DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
AbbVie Inc	Hepatitis C virus infection	Japan	Phase 2 Clinical	02-Jan-2013
AbbVie Inc	Hepatitis C virus infection	US	Phase 2 Clinical	02-Jan-2013
Enanta Pharmaceuticals Inc	Hepatitis C virus infection	US	Phase 2 Clinical	02-Mar-2010
Abbott Laboratories	Hepatitis C virus infection	Japan	Discontinued	02-Jan-2013


[Return to Table of Contents](#)







Company	Indication	Country	Development Status	Date
Abbott Laboratories	Hepatitis C virus infection	US	Discontinued	02-Jan-2013
Chiron Corp	Hepatitis C virus infection	US	Discontinued	19-May-2005


## ABT-450 CHEMICAL STRUCTURES

CAS Registry Number:	Confidence Level:
	4
	

CAS Registry Number:	Confidence Level:
	4
	
Name	Type
EA-084	Research Code

[Return to Table of Contents](#)

CAS Registry Number:	Confidence Level:
	4
	

CAS Registry Number:	Confidence Level:
	4
	

[Return to Table of Contents](#)

## ABT-450 DRUG NAMES

Names	Type
HCV protease inhibitors (capsule), Enanta/Abbott	
EA-084	Research Code
EA-058	Research Code
ABT-450	Research Code
NS3 and NS3/4A protease inhibitors, Enanta/Abbott	
HCV protease inhibitors, Chiron/Enanta	
hepatitis C virus protease inhibitors, Chiron/Enanta/Abbott	
EA-063	Research Code

## ABT-450 CLINICAL TRIALS

### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Hepatitis C virus infection											
0	0	0	0	7	10	0	5	0	0	7	15
HIV infection											
0	0	0	0	0	0	0	1	0	0	0	1

### Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	7	10	0	5	0	0	7	15

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

[Return to Table of Contents](#)

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

ABT-450 DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Enanta Pharmaceuticals Inc	1	0	1	0	2
Novartis AG	1	0	0	0	1
Abbott Laboratories	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	2	0	2

[Return to Table of Contents](#)

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
AbbVie Inc	1	0	1
Abbott Laboratories	1	0	1
Individual	1	0	1
Enanta Pharmaceuticals Inc	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Component of Combination	1
Tentative	1

[Return to Table of Contents](#)

## next generation HCV protease inhibitor, AbbVie/Enanta

### next generation HCV protease inhibitor, AbbVie/Enanta SNAPSHOT

Drug Name	next generation HCV protease inhibitor, AbbVie/Enanta
Key Synonyms	
Originator Company	AbbVie Inc
Active Companies	AbbVie Inc;Enanta Pharmaceuticals Inc
Inactive Companies	
Highest Status	Phase 1 Clinical
Active Indications	Hepatitis C virus infection
Target-based Actions	Hepatitis C virus protease inhibitor
Other Actions	
Technologies	Systemic formulation unspecified;Small molecule therapeutic
Last Change Date	09-Mar-2013

### next generation HCV protease inhibitor, AbbVie/Enanta DEVELOPMENT PROFILE

#### SUMMARY

AbbVie, in collaboration with Enanta, is developing a once-daily next generation protease inhibitor for the potential treatment of HCV infection. In November 2012, a phase I trial was initiated.

### next generation HCV protease inhibitor, AbbVie/Enanta DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
AbbVie Inc	Hepatitis C virus infection	US	Phase 1 Clinical	30-Nov-2012
Enanta Pharmaceuticals Inc	Hepatitis C virus infection	US	Phase 1 Clinical	30-Nov-2012

### next generation HCV protease inhibitor, AbbVie/Enanta DRUG NAMES

Names	Type
next generation HCV protease inhibitor, AbbVie/Enanta	

[Return to Table of Contents](#)



## modithromycin

### modithromycin SNAPSHOT

Drug Name	modithromycin
Key Synonyms	modithromycin
Originator Company	Enanta Pharmaceuticals Inc
Active Companies	Enanta Pharmaceuticals Inc
Inactive Companies	Shionogi & Co Ltd
Highest Status	Discovery
Active Indications	Neisseria gonorrhoeae infection
Target-based Actions	
Other Actions	Macrolide antibiotic
Technologies	Oral formulation;Small molecule therapeutic
Last Change Date	18-Sep-2012

### modithromycin DEVELOPMENT PROFILE

#### SUMMARY

Enanta is investigating EDP-420 for the potential treatment of Neisseria gonorrhoeae infection. In September 2012, preclinical data were presented.

Enanta, and Japanese and East Asian licensee Shionogi, were developing modithromycin (EDP-420, EP-13420, S-013420, structure shown), the oral lead from a series of bicyclic macrolide antibiotics (14-membered macrolides), for the potential treatment of respiratory tract infections,. In January 2006, a North American phase II trial started. By March 2008, Shionogi had completed a phase IIb study in Japan. The compound was still listed as in phase IIb in February 2010 ; however, in August 2010, the drug was no longer listed on Shionogi's pipeline and no recent development has been reported on the compound by Enanta.

### modithromycin DEVELOPMENT STATUS


#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Enanta Pharmaceuticals Inc	Neisseria gonorrhoeae infection	US	Discovery	11-Sep-2012
Enanta Pharmaceuticals Inc	Bacterial respiratory tract infection	North America	No Development Reported	02-Aug-2010
Shionogi & Co Ltd	Bacterial respiratory tract infection	Japan	No Development Reported	02-Aug-2010

[Return to Table of Contents](#)



## modithromycin CHEMICAL STRUCTURES

CAS Registry Number: 748796-41-0	Confidence Level: 1
	
Name	Type
modithromycin	INN; USAN
S-013420	Research Code
EDP-420	Research Code
EP-13420	Research Code

## modithromycin DRUG NAMES

Names	Type
EDP-420	Research Code
S-013420	Research Code
modithromycin	INN, USAN
EP-13420	Research Code

## modithromycin CLINICAL TRIALS

### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Bacterial respiratory tract infection											
0	0	0	0	0	2	0	1	0	0	0	3
Pneumonia											
0	0	0	0	0	2	0	0	0	0	0	2

[Return to Table of Contents](#)

## Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	3	0	1	0	0	0	4

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)


#### Phase 1 Clinical

Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## modithromycin DEALS AND PATENTS

### DEALS

#### Deals by Parent Company Chart




[Return to Table of Contents](#)

Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Enanta Pharmaceuticals Inc	1	0	0	0	1
Shionogi & Co Ltd	0	0	1	0	1

Deals by Type Chart




Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Development/Commercialization License	1	0	1

PATENTS

Patents by Parent Company Chart




Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Enanta Pharmaceuticals Inc	10	0	10
Shionogi & Co Ltd	4	0	4
Individual	2	0	2
Agennix AG	1	0	1
Tokyo University	0	1	1
Gifu University	0	1	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Process	3
General interest	3
Formulation	2
New use	2
Process (Intermediate)	2
Product	1
Component of Combination	1
Product (derivative)	1

[Return to Table of Contents](#)

## HCV polymerase inhibitors, Enanta

### HCV polymerase inhibitors, Enanta SNAPSHOT

Drug Name	HCV polymerase inhibitors, Enanta
Key Synonyms	
Originator Company	Enanta Pharmaceuticals Inc
Active Companies	Enanta Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Hepatitis C virus infection
Target-based Actions	Hepatitis C virus NS5B polymerase inhibitor
Other Actions	
Technologies	Small molecule therapeutic
Last Change Date	26-Apr-2012

### HCV polymerase inhibitors, Enanta DEVELOPMENT PROFILE

#### SUMMARY

Enanta Pharmaceuticals is investigating nucleoside and non-nucleoside HCV polymerase inhibitors, including EP-NI266, for the potential HCV infection. In February 2012, development was ongoing.

### HCV polymerase inhibitors, Enanta DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Enanta Pharmaceuticals Inc	Hepatitis C virus infection	US	Discovery	12-Jan-2009

### HCV polymerase inhibitors, Enanta DRUG NAMES

Names	Type
HCV polymerase inhibitors, Enanta	
EP-NI266	Research Code

[Return to Table of Contents](#)

## HCV cyclophilin binders/replication inhibitors, Enanta

### HCV cyclophilin binders/replication inhibitors, Enanta SNAPSHOT

Drug Name	HCV cyclophilin binders/replication inhibitors, Enanta
Key Synonyms	
Originator Company	Enanta Pharmaceuticals Inc
Active Companies	Enanta Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Hepatitis C virus infection
Target-based Actions	Peptidylprolyl isomerase inhibitor
Other Actions	Hepatitis C virus replication inhibitor
Technologies	Small molecule therapeutic
Last Change Date	04-May-2013

### HCV cyclophilin binders/replication inhibitors, Enanta DEVELOPMENT PROFILE

#### SUMMARY

Enanta Pharmaceuticals is investigating non-immunosuppressive cyclophilin binders which inhibit viral replication, including the lead EDP-546 (EP-CyP546), for the potential treatment of HCV infection,. In October 2011, development was ongoing ; in October 2012, the program was in preclinical development. In February 2013, Enanta was continuing to generate and characterize additional compounds in the discovery phase and at that time, preclinical candidate selection was expected in 2013.

### HCV cyclophilin binders/replication inhibitors, Enanta DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Enanta Pharmaceuticals Inc	Hepatitis C virus infection	US	Discovery	12-Jan-2009

### HCV cyclophilin binders/replication inhibitors, Enanta DRUG NAMES

Names	Type
HCV cyclophilin binders/replication inhibitors, Enanta	
EDP-546	Research Code
EP-CyP546	Research Code

[Return to Table of Contents](#)







## bicyclolide antibiotics (respiratory tract infection), Enanta

### bicyclolide antibiotics (respiratory tract infection), Enanta SNAPSHOT

Drug Name	bicyclolide antibiotics (respiratory tract infection), Enanta
Key Synonyms	
Originator Company	Enanta Pharmaceuticals Inc
Active Companies	Enanta Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Bacterial respiratory tract infection
Target-based Actions	
Other Actions	Macrolide antibiotic
Technologies	Antibiotic;Small molecule therapeutic
Last Change Date	31-Oct-2012

### bicyclolide antibiotics (respiratory tract infection), Enanta DEVELOPMENT PROFILE

#### SUMMARY

Enanta is investigating a series of bicyclic macrolide antibiotics (bicyclolides) for the potential treatment of hospital and community-acquired respiratory tract infections, including MRSA infections,. In October 2012, development was ongoing.

The company, in collaboration with Shionogi, was previously developing modithromycin as a lead from the series.

### bicyclolide antibiotics (respiratory tract infection), Enanta DEVELOPMENT STATUS


#### CURRENT DEVELOPMENT STATUS


Company	Indication	Country	Development Status	Date
Enanta Pharmaceuticals Inc	Bacterial respiratory tract infection	US	Discovery	19-Mar-2002


### bicyclolide antibiotics (respiratory tract infection), Enanta CHEMICAL STRUCTURES

[Return to Table of Contents](#)



CAS Registry Number:	Confidence Level:
	4
	
Name	Type
EP-017796	Research Code


CAS Registry Number:	Confidence Level:
628699-95-6	4
	
Name	Type
EP-013159	Research Code
EP-13159	Research Code

CAS Registry Number:	Confidence Level:
	4
	
Name	Type
EP-14413	Research Code

[Return to Table of Contents](#)


Name	Type
EP-014413	Research Code

CAS Registry Number:	Confidence Level:
	4




Name	Type
EP-014598	Research Code

CAS Registry Number:	Confidence Level:
	4



Name	Type
EP-014831	Research Code


CAS Registry Number:	Confidence Level:
628698-53-3	4



[Return to Table of Contents](#)


Name	Type
EP-1304	Research Code

CAS Registry Number:	Confidence Level:
628700-35-6	4




Name	Type
EP-13417	Research Code

CAS Registry Number:	Confidence Level:
628700-71-0	4



Name	Type
EP-13543	Research Code


CAS Registry Number:	Confidence Level:
	4



[Return to Table of Contents](#)


Name	Type
EP-13645	Research Code

CAS Registry Number:	Confidence Level:
	5



Name	Type
EP-1475	Research Code

CAS Registry Number:	Confidence Level:
	3



[Return to Table of Contents](#)

## bicyclolide antibiotics (respiratory tract infection), Enanta DRUG NAMES

Names	Type
EP-12371	Research Code
EP-14414	Research Code
EP-013529	Research Code
EP-13543	Research Code
bicyclic macrolide antibiotics (respiratory tract infection), Enanta	
bicyclolides (respiratory tract infection), Enanta	
EP-14008	Research Code
EP-14524	Research Code
EP-001304	Research Code
EP-01304	Research Code
EP-263	Research Code
EP-13994	Research Code
EP-13958	Research Code
EP-12355	Research Code
EP-14401	Research Code
EP-13366	Research Code
EP-12996	Research Code
EP-13043	Research Code
EP-14424	Research Code
EP-014413	Research Code
EP-13015	Research Code
EP-1112	Research Code
bicyclolide antibiotics (respiratory tract infection), Enanta	
EP-015024	Research Code
EP-015037	Research Code

[Return to Table of Contents](#)



EP-13065	Research Code
EP-14395	Research Code
EP-935	Research Code
EP-13417	Research Code
EP-13159	Research Code
EP-14452	Research Code
EP-14541	Research Code
EP-14389	Research Code
EP-014831	Research Code
EP-013159	Research Code
EP-014887	Research Code
bridged bicyclic ketolides (respiratory tract infections), Enanta	
EP-14007	Research Code
EP-13645	Research Code
EP-12344	Research Code
EP-1562	Research Code
bridged bicyclic macrolides (respiratory tract infections), Enanta	
EP-017796	Research Code
EP-14823	Research Code
EP-14124	Research Code
EP-13097	Research Code
EP-14413	Research Code
EP-1475	Research Code
EP-13118	Research Code
EP-1304	Research Code
EP-014598	Research Code
SuperMac-1	


[Return to Table of Contents](#)





**DEALS**

**Deals by Parent Company Chart**




**Deals by Parent Company Table**

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
US Government	0	0	1	0	1
Enanta Pharmaceuticals Inc	1	0	0	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Funding	1	0	1

## NS5B nucleotide polymerase inhibitors (HCV infection), Enanta

### NS5B nucleotide polymerase inhibitors (HCV infection), Enanta SNAPSHOT

Drug Name	NS5B nucleotide polymerase inhibitors (HCV infection), Enanta
Key Synonyms	
Originator Company	Enanta Pharmaceuticals Inc
Active Companies	Enanta Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Hepatitis C virus infection
Target-based Actions	Hepatitis C virus NS5B polymerase inhibitor
Other Actions	
Technologies	Small molecule therapeutic
Last Change Date	08-Feb-2013

### NS5B nucleotide polymerase inhibitors (HCV infection), Enanta DEVELOPMENT PROFILE

#### SUMMARY

Enanta is investigating NS5B nucleotide polymerase inhibitors for the potential treatment of HCV infection. In January 2013, the program was listed as being in preclinical development. In February 2013, a preclinical candidate was expected to be selected in 2013.

### NS5B nucleotide polymerase inhibitors (HCV infection), Enanta DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Enanta Pharmaceuticals Inc	Hepatitis C virus infection	US	Discovery	30-Jan-2013

### NS5B nucleotide polymerase inhibitors (HCV infection), Enanta DRUG NAMES

Names	Type
NS5B nucleotide polymerase inhibitors (HCV infection), Enanta	

[Return to Table of Contents](#)

## EDP-788 (iv prodrug, bacterial infections), Enanta Pharmaceuticals

### EDP-788 (iv prodrug, bacterial infections), Enanta Pharmaceuticals SNAPSHOT

Drug Name	EDP-788 (iv prodrug, bacterial infections), Enanta Pharmaceuticals
Key Synonyms	
Originator Company	Enanta Pharmaceuticals Inc
Active Companies	Enanta Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Bacterial infection
Target-based Actions	
Other Actions	Macrolide antibiotic
Technologies	Prodrug;Intravenous formulation;Antibiotic;Small molecule therapeutic
Last Change Date	12-Feb-2013

### EDP-788 (iv prodrug, bacterial infections), Enanta Pharmaceuticals DEVELOPMENT PROFILE

#### SUMMARY

Enanta Pharmaceuticals is investigating EDP-788, a lead bicyclolide antibiotic and the iv prodrug of EDP-322, for the potential treatment of bacterial infections, including MRSA infection, in hospital settings. In October 2012, IND enabling studies were underway. In February 2013, the company planned to file an IND and initiate phase I trials in the first half of 2014.

The company is also investigating oral EDP-788 for bacterial infections in home settings.

### EDP-788 (iv prodrug, bacterial infections), Enanta Pharmaceuticals DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Enanta Pharmaceuticals Inc	Bacterial infection	US	Discovery	30-Oct-2012

### EDP-788 (iv prodrug, bacterial infections), Enanta Pharmaceuticals DRUG NAMES


Names	Type
EDP-788 (iv prodrug, bacterial infections), Enanta Pharmaceuticals	

[Return to Table of Contents](#)



DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Enanta Pharmaceuticals Inc	1	0	0	0	1
US Government	0	0	1	0	1

[Return to Table of Contents](#)

Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Funding	1	0	1

## EDP-788 (oral prodrug, bacterial infections), Enanta

### EDP-788 (oral prodrug, bacterial infections), Enanta SNAPSHOT

Drug Name	EDP-788 (oral prodrug, bacterial infections), Enanta
Key Synonyms	
Originator Company	Enanta Pharmaceuticals Inc
Active Companies	Enanta Pharmaceuticals Inc
Inactive Companies	
Highest Status	Discovery
Active Indications	Bacterial infection
Target-based Actions	
Other Actions	Macrolide antibiotic
Technologies	Prodrug;Oral formulation;Antibiotic;Small molecule therapeutic
Last Change Date	08-Feb-2013

### EDP-788 (oral prodrug, bacterial infections), Enanta DEVELOPMENT PROFILE

#### SUMMARY

Enanta Pharmaceuticals is investigating EDP-788, a lead bicyclolide antibiotic and the oral prodrug of EDP-322, for the potential treatment of bacterial infections, including MRSA infection, in home setting. In October 2012, IND enabling studies were underway. In February 2013, an IND was expected to be filed and a phase I trial was expected to be initiated in the first half of 2014.

The company is also investigating iv EDP-788 for bacterial infections in hospital setting.

### EDP-788 (oral prodrug, bacterial infections), Enanta DEVELOPMENT STATUS

#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Enanta Pharmaceuticals Inc	Bacterial infection	US	Discovery	30-Oct-2012

### EDP-788 (oral prodrug, bacterial infections), Enanta DRUG NAMES

Names	Type
EDP-788 (oral prodrug, bacterial infections), Enanta	


[Return to Table of Contents](#)



EDP-788 (oral prodrug, bacterial infections), Enanta DEALS AND PATENTS

DEALS

Deals by Parent Company Chart




Deals by Parent Company Table

Company Name	Principal		Partner		Total
	Active	Inactive	Active	Inactive	
Enanta Pharmaceuticals Inc	1	0	0	0	1
US Government	0	0	1	0	1

[Return to Table of Contents](#)



Deals by Type Chart



Deals by Type Table

Deal Type	Active	Inactive	Total
Drug - Funding	1	0	1

## EDP-322

### EDP-322 SNAPSHOT

Drug Name	EDP-322
Key Synonyms	
Originator Company	Enanta Pharmaceuticals Inc
Active Companies	Enanta Pharmaceuticals Inc
Inactive Companies	
Highest Status	Suspended
Active Indications	Gram positive bacterium infection
Target-based Actions	
Other Actions	Macrolide antibiotic
Technologies	Oral formulation;Antibiotic;Small molecule therapeutic
Last Change Date	31-Oct-2012

### EDP-322 DEVELOPMENT PROFILE

#### SUMMARY

Enanta Pharmaceuticals was developing EDP-322, an oral formulation of the bicyclolide (bridged bicyclic ketolide) antibiotic EDP-MRSA-1, for the potential treatment of Gram-positive bacterial infections including Methicillin-resistant Staphylococcus aureus (MRSA) infection and vancomycin resistant Enterococcus (VRE) infection. In September 2008, the company began a phase Ia trial ; by October 2009, the trial was completed. In February 2012, development was ongoing ; however, in October 2012, Enanta decided to focus its current development activities on iv and oral formulations of EDP-788 and therefore, development of EDP-322 was presumed to be suspended.

### EDP-322 DEVELOPMENT STATUS


#### CURRENT DEVELOPMENT STATUS

Company	Indication	Country	Development Status	Date
Enanta Pharmaceuticals Inc	Gram positive bacterium infection	US	Suspended	30-Oct-2012

### EDP-322 CHEMICAL STRUCTURES

[Return to Table of Contents](#)



CAS Registry Number:	Confidence Level:
	4
	
Name	Type
EP-16322	Research Code

## EDP-322 DRUG NAMES

Names	Type
antibacterial (oral, Gram-positive infections), Enanta	
EDP-322	Research Code
EP-16322	Research Code
EDP-MRSA-1 (oral), Enanta	

## EDP-322 CLINICAL TRIALS

### Trials by Phase and Condition Studied

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Skin infection											
0	0	0	0	0	0	0	1	0	0	0	1
Gram positive bacterium infection											
0	0	0	0	0	0	0	1	0	0	0	1
MRSA infection											
0	0	0	0	0	0	0	1	0	0	0	1

[Return to Table of Contents](#)

## Total Trials by Phase and Status

Phase 4 Clinical		Phase 3 Clinical		Phase 2 Clinical		Phase 1 Clinical		Phase Unspecified		Total	
On-going	All	On-going	All	On-going	All	On-going	All	On-going	All	On-going	All
Total by Phase and Status											
0	0	0	0	0	0	0	3	0	0	0	3

### Phase Definitions

#### Phase 3 Clinical

Includes Phase 3, Phase 3b, Phase 3a, Phase 2/3 (where enrolment count is 300 or over)

#### Phase 2 Clinical

Includes Phase 2, Phase 2a, Phase 2b, Phase 1/2 (where enrolment count is 100 or over), Phase 2/3 (where enrolment count is under 300 or not specified)

#### Phase 1 Clinical


Includes Phase 1, Phase 1a, Phase 1, Phase 1/2 (where enrolment count is under 100 or not specified), Phase 0

## EDP-322 DEALS AND PATENTS

### PATENTS

#### Patents by Parent Company Chart

Chart displayed by Owner/Third Party




#### Patents by Parent Company Table

Company Name	As Owner	As Third Party	Total
Enanta Pharmaceuticals Inc	1	0	1
Individual	1	0	1

[Return to Table of Contents](#)

Patents by Drug Relationship Type Chart



Patents by Drug Relationship Type Table

Drug Relationship	Total
Tentative	1

[Return to Table of Contents](#)

This report was created by Thomson Reuters, using information from *Thomson Reuters Cortellis™ for Competitive Intelligence*; a comprehensive, proven intelligence solution that leverages the most accurate, complete, and widely respected drug pipeline information.

For more information about *Cortellis for Competitive Intelligence*, visit:

[http://cortellis.thomsonreuters.com/cortellis\\_for\\_you/?cid=thomsonone](http://cortellis.thomsonreuters.com/cortellis_for_you/?cid=thomsonone).

For subscription information, e-mail [scientific.lifesciences@thomsonreuters.com](mailto:scientific.lifesciences@thomsonreuters.com).

© 2012 Thomson Reuters. All rights reserved.  
Republication or redistribution of Thomson Reuters content, including by framing or similar means, is prohibited without the prior written consent of Thomson Reuters. 'Thomson Reuters' and the Thomson Reuters logo are registered trademarks and trademarks of Thomson Reuters and its affiliated companies.

[Return to Table of Contents](#)

